In its healthy state, the Extracellular Matrix (ECM) is an intricate web of fibrous strands that support and connect every cell in our tissues. This network is an active environment that regulates cell behavior, nutrient exchange, and tissue repair.
It is human scaffolding.
These fibers are made from specialised proteins and glycoproteins, forming a
flexible and dynamic architecture.
They are constantly maintained and
remodeled to keep tissues resilient and responsive to the body’s needs.
In chronic disease, this once supportive architecture begins to turn against you.
The structure and composition of the ECM changes to become thicker and stiffer. The ECM stops helping and starts hurting— amplifying harmful signals, walling off effective repair, and pushing cells to behave abnormally.
A diseased ECM isn’t just a passive bystander. It's an active participant in driving pathologies like inflammation, fibrosis and cancers.
Within this altered environment lie three therapeutic opportunities.
Structural
Cellular
Bioactive
The ECM Platform
Using our platform technology, we have the unique ability to use tissue- and disease-specific human ECM scaffolds to model and study the mechanisms driving disease biology.
Pipeline
The assets being developed in our discovery stage portfolio target disease-specific changes within the ECM, with the aim of improving clinical outcomes in patients with fibrosis, inflammation and solid tumours.
Partnerships
We are interested in forming collaborations with pharma and biotech companies to unleash the full discovery potential of our platform and expand into additional therapeutic areas.
Learn how we are unlocking unprecedented therapies for chronic diseases